Truist Financial Reiterates a Buy on Harmony Biosciences (HRMY)

​Harmony Biosciences Holdings, Inc. (NASDAQ:HRMY) is one of the Best Beaten Down Growth Stocks to Buy According to Analysts. On October 24, Danielle Brill from Truist Financial reiterated a Buy rating on Harmony Biosciences Holdings, Inc. (NASDAQ:HRMY) without disclosing any price targets.

The rating follows the company’s pre-announcement of strong Q3 2025 WAKIX performance on October 23. The franchise generated around $239 million in revenue during the third quarter, reflecting 29% year-over-year growth. Management noted that these results were driven by a record rise in the average number of patients. The number of patients increased by 500 during the quarter to reach 8,100 average patients.

​In addition, Harmony Biosciences Holdings, Inc. (NASDAQ:HRMY) also increased its revenue guidance for 2025 to a range of $845 million – $865 million versus the previous range of $820 million – $860 million.

​Harmony Biosciences Holdings, Inc. (NASDAQ:HRMY) develops and commercializes therapies for rare neurological diseases and other unmet medical needs.

READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now.

Disclosure: None. This article is originally published at Insider Monkey.